查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1953717

組織工程市場－全球產業規模、佔有率、趨勢、機會、預測：依材料類型、應用、最終用戶、地區和競爭格局分類，2021-2031年

Tissue Engineering Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Material Type, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球組織工程市場預計將從 2025 年的 140.2 億美元大幅成長至 2031 年的 240.5 億美元，複合年成長率為 9.41%。

這個交叉學科領域結合了細胞、工程材料和生物化學因子，旨在恢復或改善生物功能，其發展動力主要來自慢性疾病的日益增多和全球人口老化。此外，器官捐贈的嚴重短缺也大大促進了這一領域的成長，增加了對生物替代療法的需求。根據器官捐贈網路聯盟（Organ Donation Network Coalition）預測，截至2025年，“將有超過10萬名候選人等待挽救生命的器官移植”，這凸顯了大規模創新技術的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 140.2億美元
市場規模：2031年 240.5億美元
複合年成長率：2026-2031年 9.41%
成長最快的細分市場 整形外科
最大的市場 北美洲

然而，由於產品核准所需的監管流程複雜且嚴格，該行業面臨許多重大障礙。研發和長期臨床試驗所需的大量資金可能會抑制投資，並延緩新治療方法的上市。因此，克服不同國際司法管轄區嚴格的合規標準和報銷不確定性，構成了阻礙該領域快速發展的重大障礙。

市場促進因素

3D生物列印和生物製造技術的快速發展，正從根本上改變這一領域，使複雜且功能性的組織結構能夠精確地建構。這些進步克服了以往在規模化和血管生成方面面臨的挑戰，並使得大規模生產能夠忠實模擬自然生物學的組織結構成為可能。 CollPlant Biotechnologies公司於2024年6月發布的新聞稿「CollPlant成功生物印出200cc商用尺寸的再生乳房植入」是一個很好的例證。該公司成功生物列印出200cc的再生乳房植入，標誌著軟組織填充的商業性規模化應用邁出了重要一步，並引領業界走向實用且可植入的解決方案。

同時，政府和私人機構對再生醫學研發投入的增加，正成為市場成長的主要驅動力。這些資金的注入對於維持高風險研究以及建造先進生物製造所需的專業基礎設施至關重要。例如，英國研究與創新署（UKRI）在2024年2月發布的題為《一項新的1億英鎊基金釋放生物技術的潛力》的報告中，承諾投入1億英鎊建立一個新的生物技術和生物醫學中心。在全球範圍內，這項投資一直保持穩定。根據再生醫學聯盟2024年的報告，該領域在今年上半年吸引了約109億美元的投資，顯示人們對下一代治療方法的商業性前景仍然充滿信心。

市場挑戰

嚴格的法規結構和巨額的研發成本對全球組織工程市場的成長構成了重大挑戰。生物替代療法的開發必須符合世界衛生組織制定的嚴格安全性和有效性標準，這需要進行複雜而漫長的臨床試驗。這些苛刻的要求必然會帶來巨額的資金投入，使得研發人員獲得監管部門的核准成為一條耗資巨大且耗時漫長的道路。

因此，這種充滿挑戰的商業環境直接阻礙了行業擴張，因為它設置了准入壁壘並抑制了投資。核准時間的不確定性以及後期臨床試驗的高失敗風險尤其影響中小企業，限制了創新所需的資金流入。根據再生醫學聯盟（Alliance for Regenerative Medicine）統計，2024年上半年全球再生醫學領域的投資額達到109億美元，與疫情尖峰時段相比，早期企業的資金籌措環境更加緊張。資金支持的減少迫使許多公司推遲商業化進程或終止前景看好的治療項目，導致整體市場發展放緩。

市場趨勢

用於藥物篩檢的「晶片器官」平台的興起，透過提供標準化的人體組織模型，減少了對動物實驗的依賴，正在革新臨床前試驗。這一趨勢正引領產業邁向高通量商業系統，這些系統能夠模擬系統性交互作用，從而進行精準的毒性分析，使藥物研發人員能夠儘早獲得可預測的代謝數據，從而降低臨床試驗失敗的風險。根據CN Bio於2025年10月發布的新聞稿《CN Bio發布一體化晶片器官系統》，該公司推出了“PhysioMimix Core”，這是一個整合系統，能夠同時對多達288個樣本進行高通量篩檢，從而支持複雜的多器官實驗，並加速治療方法的檢驗。

將人工智慧 (AI) 整合到支架結構設計中，正在提升生物製造組織的功能品質。生成式 AI 模型被用來定義複雜的微結構，從而實現滿足營養擴散和細胞活力等關鍵要求的支架設計，同時也能透過自適應製造系統進行即時參數調整。例如，在 Bioengineer.org 於 2025 年 9 月發表的報導「AI 將印表機轉變為組織工程的協作工具」的文章中，研究人員開發了一種名為「GRACE」的 AI 驅動的體積生物列印系統。該系統利用生成式模型合成最佳組織設計，並在列印過程中自適應地糾正缺陷，從而能夠創建以前無法實現的具有活性的血管結構。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球組織工程市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依材料類型（合成材料、生物來源材料、其他）
    • 依應用領域（整形外科、肌肉骨骼系統/脊椎、神經科、心臟科、皮膚/覆蓋組織、其他）
    • 依最終用戶（醫院、癌症研究中心、學術/研究機構等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美組織工程市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲組織工程市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區組織工程市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲組織工程市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲組織工程市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球組織工程市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Zimmer Biomet Holdings Inc.
  • Stryker Corporation Holdings
  • 3D BioFibR Inc.
  • Integra LifeSciences Corporation
  • CollPlant Biotechnologies Ltd.
  • AbbVie Inc.
  • Becton, Dickinson and Company
  • Athersys, Inc.
  • BioTissue Holding Inc.
  • Japan Tissue Engineering Co., Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17591

The Global Tissue Engineering Market is projected to expand significantly, growing from USD 14.02 Billion in 2025 to USD 24.05 Billion by 2031, representing a CAGR of 9.41%. This multidisciplinary field, which combines cells, engineering materials, and biochemical factors to restore or improve biological functions, is largely propelled by the increasing prevalence of chronic diseases and an aging global population. Furthermore, the critical shortage of donor organs serves as a major catalyst for growth, driving the need for biological substitutes; according to the 'United Network for Organ Sharing', in '2025', 'more than 100,000 candidates are currently awaiting life-saving organ transplants', underscoring the urgent demand for scalable innovations.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 14.02 Billion
Market Size 2031USD 24.05 Billion
CAGR 2026-20319.41%
Fastest Growing SegmentOrthopedics
Largest MarketNorth America

However, the industry faces substantial obstacles due to the complex and stringent regulatory pathways necessary for product approval. The immense financial outlay required for research, development, and protracted clinical trials can discourage investment and postpone the launch of new therapies. Consequently, maneuvering through these rigorous compliance standards and reimbursement uncertainties across various international jurisdictions presents a significant barrier that could hinder the sector's rapid expansion.

Market Driver

Rapid technological progress in 3D bioprinting and bio-fabrication is fundamentally transforming the sector by facilitating the precise creation of complex, functional tissue structures. These advancements resolve historical issues related to scalability and vascularization, enabling the production of large-scale tissue constructs that closely emulate natural biology. A prime example occurred in June 2024, when CollPlant Biotechnologies announced in their 'CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants' press release that they had successfully bioprinted 200cc regenerative breast implants, marking a pivotal step toward commercial scalability for soft tissue reinforcement and moving the industry toward viable, implantable solutions.

Simultaneously, increasing government and private funding for regenerative medicine R&D is acting as a primary driver for market growth. This capital infusion is crucial for sustaining high-risk research and building the specialized infrastructure needed for advanced bio-manufacturing. For instance, according to UK Research and Innovation's 'New £100m fund will unlock the potential of engineering biology' announcement in February 2024, the organization committed £100 million to establish new mission hubs for engineering biology and biomedicine. Globally, this financial commitment remains strong; the Alliance for Regenerative Medicine reported in 2024 that the sector attracted roughly $10.9 billion in investment during the first half of the year, indicating continued confidence in the commercial prospects of these next-generation therapies.

Market Challenge

Stringent regulatory frameworks and the exorbitant costs associated with research and development pose a major challenge to the growth of the Global Tissue Engineering Market. Creating biological substitutes demands compliance with rigorous safety and efficacy standards set by international health authorities, which necessitates complex and extended clinical trials. These strict requirements inevitably result in immense financial expenditures, rendering the path to regulatory approval both capital-intensive and time-consuming for developers.

As a result, this difficult operating environment directly hinders industry expansion by establishing barriers to entry and discouraging investment. The uncertainty regarding approval timelines and the high risk of failure in late-stage trials limit the capital flow necessary for innovation, particularly affecting small and medium-sized enterprises. According to the 'Alliance for Regenerative Medicine', in '2024', 'global investment in the regenerative medicine sector reached USD 10.9 billion in the first half of the year, reflecting a constrained funding landscape for early-stage companies compared to pandemic-era peaks'. This decline in financial support compels many firms to postpone commercialization efforts or discontinue promising therapeutic programs, effectively decelerating overall market progression.

Market Trends

The rise of Organ-on-a-Chip platforms for drug screening is revolutionizing preclinical testing by offering standardized human tissue models that reduce dependence on animal studies. This trend steers the sector toward high-throughput commercial systems that simulate systemic interactions for precise toxicity profiling, allowing pharmaceutical developers to mitigate clinical trial failures by securing predictive metabolic data early. According to CN Bio's 'CN Bio launches all-in-one Organ-on-a-chip system' press release in October 2025, the company introduced the PhysioMimix Core, a unified system capable of high-throughput screening for up to 288 samples simultaneously, thereby enabling complex multi-organ experiments and accelerating therapeutic validation.

The integration of Artificial Intelligence into scaffold architecture design is enhancing the functional quality of bio-fabricated tissues. Generative AI models are being employed to define complex micro-architectures, ensuring that scaffolds satisfy critical requirements for nutrient diffusion and cell viability while enabling adaptive manufacturing systems to adjust parameters in real-time. For example, according to the 'AI Transforms Printers into Collaborative Tools for Tissue Engineering' article by Bioengineer.org in September 2025, researchers created 'GRACE', an AI-driven volumetric bioprinting system that utilizes generative models to synthesize optimal tissue designs and adaptively correct defects during printing, facilitating the creation of viable, vascularized structures that were previously unattainable.

Key Market Players

  • Zimmer Biomet Holdings Inc.
  • Stryker Corporation Holdings
  • 3D BioFibR Inc.
  • Integra LifeSciences Corporation
  • CollPlant Biotechnologies Ltd.
  • AbbVie Inc.
  • Becton, Dickinson and Company
  • Athersys, Inc.
  • BioTissue Holding Inc.
  • Japan Tissue Engineering Co., Ltd

Report Scope

In this report, the Global Tissue Engineering Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tissue Engineering Market, By Material Type

  • Synthetic Materials
  • Biologically Derived Materials
  • Others

Tissue Engineering Market, By Application

  • Orthopedics
  • Musculoskeletal & Spine
  • Neurology
  • Cardiology
  • Skin & Integumentary
  • Others

Tissue Engineering Market, By End User

  • Hospitals
  • Cancer Research Centers
  • Academic and Research Institutes
  • Others

Tissue Engineering Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tissue Engineering Market.

Available Customizations:

Global Tissue Engineering Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tissue Engineering Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Material Type (Synthetic Materials, Biologically Derived Materials, Others)
    • 5.2.2. By Application (Orthopedics, Musculoskeletal & Spine, Neurology, Cardiology, Skin & Integumentary, Others)
    • 5.2.3. By End User (Hospitals, Cancer Research Centers, Academic and Research Institutes, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Tissue Engineering Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Material Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Tissue Engineering Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Material Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Tissue Engineering Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Material Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Tissue Engineering Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Material Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Tissue Engineering Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Material Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Tissue Engineering Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Material Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. France Tissue Engineering Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Material Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Tissue Engineering Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Material Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Tissue Engineering Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Material Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Tissue Engineering Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Material Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia Pacific Tissue Engineering Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Material Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Tissue Engineering Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Material Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Tissue Engineering Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Material Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Tissue Engineering Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Material Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Tissue Engineering Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Material Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Tissue Engineering Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Material Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. Middle East & Africa Tissue Engineering Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Material Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Tissue Engineering Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Material Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Tissue Engineering Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Material Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Tissue Engineering Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Material Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. South America Tissue Engineering Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Material Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Tissue Engineering Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Material Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Tissue Engineering Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Material Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Tissue Engineering Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Material Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Tissue Engineering Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Zimmer Biomet Holdings Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Stryker Corporation Holdings
  • 15.3. 3D BioFibR Inc.
  • 15.4. Integra LifeSciences Corporation
  • 15.5. CollPlant Biotechnologies Ltd.
  • 15.6. AbbVie Inc.
  • 15.7. Becton, Dickinson and Company
  • 15.8. Athersys, Inc.
  • 15.9. BioTissue Holding Inc.
  • 15.10. Japan Tissue Engineering Co., Ltd

16. Strategic Recommendations

17. About Us & Disclaimer